Drug Trial Radar · NCT06097663
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Feb 15, 2024
Primary completion
Oct 27, 2024
Study completion Nov 4, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (variant allele frequency \[VAF\] ≥2%).
Conditions
- Coronary Heart Disease
- Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Interventions
MAS825Drug
Active MAS825 single dose
MAS825 PlaceboDrug
MAS825 placebo single dose
DFV890Drug
Oral tablet of DFV890 active once daily
DFV890 placeboDrug
Oral tablet of DFV890 placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax ModelTime frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
- Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax ModelTime frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
- Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression ModelTime frame: Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Washington University
St Louis, Missouri
Vanderbilt University Medical Cent
Nashville, Tennessee
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.